Lilly will sell a version of its popular insulin at half the price, but will this appease critics?

(By Ed Silverman for STAT)

As drug makers come under increasing pressure to lower prices, Eli Lilly (LLY) is trying to thread a needle by introducing a new version of insulin at half the list price.  Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.